Kornimate/medical-research-clean huggingface dataset:
smart technology facilitated venous thromboembolism prophylaxis based on bundled evidence-based prevention strategies

Conditions: Venous Thromboembolism; Clinical Decision Support Systems; Digital Health

Summary: venous thromboembolism (vte) is the third leading cause of cardiovascular disease deaths globally, and its incidence is increasing over the years. hospital-acquired vte accounts for approximately 75% of all deaths attributed to vte. however, only half of patients with indications for vte prophylaxis take preventive measures, and high rates of inappropriate vte prophylaxis prescribing contribute to the gap between vte prophylaxis and guidelines. to further minimize the gap between clinical practice and guidelines, a range of strategies have been employed across various fields of vte prophylaxis. one of the most effective measures is the utilization of a clinical decision support system (cdss). smart technology-based cdss facilitates automated evaluation of vte risk and detection, addressing issues at both the beginning and end of the in-hospital vte prevention process. but there is still a lack of research on how to effectively implement evidence-based vte prophylaxis in the middle of the process. in our hospital, routine use of devtecare system (a cdss for vte risk assessment and integrated care) for in-hospital management of vte has been launched since 2021. this study aims to investigate the effect of integrating bundled guideline-based vte prevention strategies into the devtecare system on in-hospital vte prophylaxis.


Eligibility criteria:
inclusion criteria: * discharged patients who were ≥18 years of age at admission were included in the observation cohort. if a patient had multiple hospitalizations, information on only the longest hospitalization was included in the study. exclusion criteria: * lack of diagnostic information； * length of hospitalization ≤ 24 hours； * patients on anticoagulation therapy at the time of admission: e.g., those with established vte, atrial fibrillation, acute myocardial infarction, ischemic stroke, those on continuous renal replacement therapy, extracorporeal membrane pulmonary oxygenation, hemodialysis, and mechanical valve implantation status.

Keywords: venous thromboembolism clinical decision support systems prophylaxis
the automated fluid shunt (afs)in chronic congestive heart failure

Conditions: Congestive Heart Failure; Ascites

Summary: a 28-week, feasibility study to investigate the safety and efficiency of the automatic fluid shunt in patients with chronic congestive heart failure, ascites and diuretic resistance.


Eligibility criteria:
inclusion criteria: * female or male patients ≥ 18 years of age * a clinical diagnosis of chronic congestive heart failure \> 6 months * at least one episode of documented adhf during the previous 6 months * nyha functional class iii-iv * circulating levels of nt-probnp ≥ 800 ng/l. * stable, optimized therapy for heart failure for at least 4 weeks prior to enrollment * echocardiography performed within 3 months * detectable ascites by ultrasound and/or computed tomography * diuretic resistance defined as a daily dose of furosemide \> 80 mg, torsemide \> 40 mg or bumetanide \> 2 mg * written informed consent exclusion criteria: * present or recurring systemic or local infection, such as peritonitis, urinary tract infection, or abdominal skin infection. * ongoing malignant disease with adverse prognosis * evidence of firmly loculated peritoneal effusion. * obstructive uropathy * severely reduced renal function (s-creatinine 300 mol/l) or end-stage renal disease requiring dialysis * severe liver disease (asat and/or alat and/or total bilirubin three times upper limit of normal range laboratory values) * pregnancy * requirement for intravenous inotropes * acute coronary syndrome or any condition requiring emergency treatment * heart disease requiring surgical intervention during the course of the study * any other clinically significant disease that could be adversely affected by study participation judged by the investigator
a prospective multicenter study on patients'satisfaction with angeliq® micro in real clinical practice conducted in russia

Conditions: Menopause

Summary: to evaluate the patients' satisfaction with angeliq micro in real clinical practice after 13 cycles of treatment.

this non-interventional study is planned with the aim of obtaining information about the results of the product use in real clinical practice by means of the evaluation of the patients' satisfaction. the study will be multicenter, non-interventional, prospective, cohort study in patients for whom their physicians have taken a decision about angeliq micro treatment, irrespectively of the fact of this study inclusion. the absence of a control group (patients who receive another menopausal hormonal therapy medication, or do not receive menopausal hormonal therapy at all) is based on high risk of bias (heterogeneity of exposure in case of comparison of low-dosed and ultralow-doses menopausal hormonal therapy regiments, or in case of comparison with a group of patients for whom the menopausal hormonal therapy is not indicated).

Eligibility criteria:
inclusion criteria: * female patients aged 50 to 65 years with vasomotor symptoms of menopause (moderate or severe in intensity), who has been prescribed or will be prescribed the menopausal hormonal therapy with angeliq micro. * patients, who are already receiving continuous combined menopausal hormonal therapy (except angeliq) for 3-5 years willing to continue mht, and who will change their therapy for angeliq micro. * patients who never ever received menopausal hormonal therapy, if at least 3 years have passed after the last menstruation, with the straw+10 stage +1c and younger than 60 years at the moment of inclusion. * signed informed consent form (written consent for the study participation). exclusion criteria: * unwillingness or inability to give the informed consent for the study participation. * contraindications for menopausal hormonal therapy (according to the angeliq micro smpc). * current use or history of use during 1 month before of dietary supplements containing st john's wort, as they can affect tolerability and safety of hormonal therapy. * current participation in any other clinical study

Keywords: non-interventional cohort angeliq micro menopause russia
a phase ii study of an otic formulation in treating peri-operative tube otorrhea

Conditions: Acute Otitis Media

Summary: the purpose of this study is to determine if an otic formulation is safe and effective in treating peri-operative tube otorrhea.


Eligibility criteria:
inclusion criteria: * 6 months to 12 years old * diagnosed with recurrent acute otitis media or chronic otitis media with effusion * must be first set of ear tubes. * patient may not have had any other previous otologic-related surgery. * ear tube may not be silver oxide, silver salt, t-type tube or long-shafted tube * patient may not have existing perforation of the eardrum. * patient must not require another surgical procedure other than myringotomy and tube insertion. * patient may not be a menarchal female * diabetic patients are not eligible * patient may not have any disease or condition that would negatively affect the conduct of the study * patient may not require any other systemic antimicrobial therapy during the study. * patient must meet certain medication washouts to be eligible * analgesic use (other than acetaminophen) is not allowed * patient may not be pre-disposed to neurosensory hearing loss * other protocol-defined inclusion criteria may apply exclusion criteria: * age * other protocol-defined exclusion criteria may apply

Keywords: ear tubes ear infection ear drops ear tube surgery acute otitis media
impact of continuous positive airway pressure on breathing motion amplitude

Conditions: Cancer

Summary: this study involves a breathing motion assessment in healthy subjects before and after continuous positive airway pressure (cpap) administration using mri images. the hypothesis for this study is that cpap administration will significantly reduce breathing motion. this may help cancer patients who are undergoing proton radiotherapy, so they possibly will not have to hold their breath during the procedure.

minimally invasive techniques for tumor motion reduction that involve free-breathing patients have significant relevance in the context of radiation therapy, in particular proton radiotherapy. tumor motion reduction has favorable implications for reduction of radiation doses to adjacent healthy organs, radiation plan robustness (accuracy/quality) and for treatment efficiency (reduction of treatment times). using non-ionizing mri with volunteers, the investigators will determine the extent to which continuous positive airway pressure (cpap) reduces breathing motion (diaphragmatic excursion). the researchers will also investigate the parameter space associated with breathing motion reduction versus the amount of pressure applied, as well as timing of initiation of cpap in relation to the imaging time point (to address whether an initial transient breathing state exists).

Eligibility criteria:
inclusion criteria: 1. healthy adult female and males 2. subject meets routine mri safety criteria exclusion criteria: 1. age \<18 2. known history of chronic obstructive pulmonary disease (copd), asthma, or other chronic pulmonary illness 3. pregnancy 4. any safety risk identified via mri safety screening

Keywords: continuous positive airway pressure radiotherapy proton therapy
dispervise ophthalmic viscoelastic as an agent to ensure watertight wound closure after clear corneal cataract incisions

Conditions: Cataracts

Summary: the purpose of this study is to look at the ability of viscoat to ensure proper wound closure.


Eligibility criteria:
inclusion criteria: * ability to provide informed consent, complete questionnaires, and likely to complete all visits * subject must be male or female, of any race, and at least 21 years old * undergoing uncomplicated cataract surgery with clear corneal incisions exclusion criteria: * subjects with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course * acute or chronic disease or illness that would increase risk or confound study results (e.g., uncontrolled diabetes mellitus, immunocompromised,etc.) * uncontrolled systemic disease * corneal abnormalities (e.g., stromal, epithelial or endothelial dystrophies) * subjects who use concurrent topical or systemic medications that may impair healing, including but not limited to:antimetabolites,isotretinoin (accutane) within 6 months of treatment, and amiodarone hydrochloride (cordarone) within 12 months of treatment * subjects with a history of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or simplex, endocrine disorders (including but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis * concurrent participation or participation in the last 30 days in any other clinical trial
phenotypic characterization and biomarkers investigation for eosinophilic esophagitis in pediatric patients

Conditions: Eosinophilic Esophagitis; Gastroesophageal Reflux

Summary: the purpose of this study is to find out some potential biomarkers for the eosinophilic esophagitis (eoe) in pediatric patients through the prospective clinical characterization and assessment of samples collected during the diagnostic process

this study collects clinical information from pediatric patients between 0-18 years old who have been undergoing upper gastrointestinal endoscopy due to general complaints. the demographic, clinical symptoms, endoscopy, ph monitoring, and histology data are assessed during the diagnostic process. in the baseline endoscopy procedure samples (blood, saliva, esophageal tissue, and esophageal mucus) are taken. after diagnostic process of eoe and gastroesophageal reflux disease (gerd) supported by international guidelines the patients are divided into three groups - eoe, gerd, and control. the techniques are used for patients characterization and assessment: 1. symptoms score: general symptom score and/or pediatric eosinophilic esophagitis symptom score (peess v2.0) - translated and adapted version for brazilian portuguese 2. endoscopic score: eosinophilic esophagitis (eoe) endoscopic reference score (erefs) 3. peak eosinophil count (pec) and histological features description 4. proteomic analyses 5. microbiome analyses 6. immunohistochemistry analyses

Eligibility criteria:
inclusion criteria: * pediatric patients who are undergoing upper gastrointestinal endoscopy for diagnostic purpose exclusion criteria: * pediatric patients who are undergoing upper gastrointestinal endoscopy for therapeutic procedures * the presence of other eosinophilic diseases * patients have been taken corticosteroids and/or gastric acid secretion inhibition drugs for the last four weeks

Keywords: eosinophilic esophagitis gastroesophageal reflux diagnose biomarker
effect of selective cox-2 inhibition on ulcer healing

Conditions: Arthritis; Gastric Ulcer

Summary: the purpose of this study is to compare the effect of famotidine plus a cox-2 inhibitor (celecoxib) with famotidine plus dologesics in ulcer healing in arthritis patients.

for many years the integrity of the stomach mucosal barrier is thought to be maintained by mucosal prostaglandins (pg) synthesized by cox-1. however, the notion that cox-1 protects the stomach and cox-2 induces inflammation may be over-simplistic. in animal studies, cox-2, but not cox-1, is expressed in experimental gastric ulcer. inhibition of cox-2 delays ulcer healing, indicating that pg derived from cox-2 contributes to restoring the mucosal barrier \[1\]. whether this animal observation can be generalized to the human stomach is unknown. to date the biological functions of cox-1 and cox-2 in the healing of human gastric ulcer healing is unclear. unlike experimental ulcers that only express cox-2, recently we have shown that both cox-1 and cox-2 are up-regulated in human gastric ulcers \[2\]. furthermore, our preliminary results suggest that inhibition of cox-2 alone may not lead to a clinically significant delay in ulcer healing (refer to progress report). these observations suggest that peptic ulcer healing is more complex in the human stomach - both cox isoforms may be involved in the healing process. inhibition of cox-2 alone may have less adverse effect than non-selective inhibition of both cox isoforms in ulcer healing. the current study aims to resolve the functional significance of cox-2 in human gastric ulcer from a biological and clinical perspective.

Eligibility criteria:
inclusion criteria: * gastric ulcers confirmed by endoscopy * stop taking nsaids for 1 week prior to endoscopy * age 18 * h. pylori negative * informed written consent exclusion criteria: * actively bleeding ulcers * ulcers showing dysplasia or malignancy * renal failure (serum creatinine \>200umol/l) * previous gastric surgery * moribund or terminal malignancy * concomitant use of proton pump inhibitor, misoprostol, aspirin, steroid or anticoagulant

Keywords: celecoxib arthritis ulcer healing
postoperative pain after conservative root canal preparation

Conditions: Periapical Diseases; Periapical Periodontitis; Postoperative Pain; Pulp Necroses; Flare Up, Symptom

Summary: the goal of this clinical trial is to compare the pain experienced by healthy participants after root canal treatment with small versus large root canal sizes. the main questions it aims to answer are: 1. do small and large root canal sizes cause different pain levels? 2. what is the number of painkiller pills taken by each participant? 3. does small root canal size cause severe pain and facial swelling? the researcher will perform root canal treatment on lower molar teeth. the researcher will ask about the pain level, painkiller pill number, and swelling on the 6th,12th, 24th, 48th, 72nd hours, and 7th day after the treatment.

root canal shaping is an essential step for root canal treatment. necrotic tissues, debris, microorganisms, and organic matter should be removed to clean and disinfect the root canals. previously, this conventional procedure involved removing excessive dentine from root canals, which weakened the tooth's structural integrity. due to technological advances, excessive dentine removal is not always necessary. root canals are claimed to be disinfected despite minimal dentine removal. this concept of treatment is called minimally invasive or conservative root canal treatment. this study compares postoperative pain after conservative and conventional root canal preparation in healthy participants with necrotic mandibular molars. participants will be enrolled after clinical and radiographic examination by an independent endodontist and allocated randomly to conventional or conservative root canal treatment groups. after the root canal treatment, the researcher will send the participants an online questionnaire on the 6th,12th, 24th, 48th, and 72nd hours and 7th day and ask them to rate their pain score according to the numerical rating system and the number of painkillers they have taken. the flare-up rate will be determined according to the presence of swelling and severe pain. an experienced endodontist not involved in the research will monitor eligible participants and clinical treatment protocol.

Eligibility criteria:
inclusion criteria: * mandibular molar tooth * asymptomatic apical periodontitis * pulp necrosis * periapical lesion index 4 (visible and well-defined periapical lesion) * absence of pretreatment pain exclusion criteria: * symptomatic apical periodontitis * preoperative pain * sinus tract * pulpitis * acute apical abscess * tooth not being in occlusion * external and internal root resorption * open apices * periodontal probing depth of more than 4 mm * initial apical file larger than 15 and 20 k-file for mesial and distal canals respectively * chronic illness, analgesic allergy, prior analgesic and antibiotics usage 12 hours and 3 months before treatment, respectively

Keywords: pain nickel titanium (niti) conservative root canal treatment minimally invasive flare-up analgesic
divided attention steering simulator alertness test

Conditions: Sleep Apnea, Obstructive

Summary: driving simulator programmes are used under a wide range of conditions, and a correlation of driving performance and real accident risks in patients with obstructive sleep apnoea syndrome(osas)could be shown. the most frequently used driving simulator is the divided attention steering simulator (dass) of stowood scientific instruments ltd. (ssi). until today there are no reference levels with regards to sex and age in existence. to define the boundaries of normality age and sex reference values are to be generated and compared to values of patients with osas. 50 male and 50 female healthy subjects (10 of each age decade between 20 and 70 years) will perform the dass for 30 minutes. in the other arm 100 osas patients will perform the test as well. a better differentiation of pathologic driving performance and response times of osas patients should be possible with new reference levels.

the dass programme records several data, including mean and absloute errors and standard deviations from centre and curve. additionally the response time to a randomly appearing target number is recorded (divided attention). the standard deviation (curve) is the difference between the steering angle and the road angle. standard deviation (centre) is the standard deviation of the centre of the car from the centre of the road. steering performance is quantified as the standard deviation of the error from a theoretical perfect path. the secondary task of the divided attention test is to respond to a randomly appearing target number at the sides of the monitor while trying to keep the car in the centre of the road. average reaction time is the average time (in seconds) it takes the subject to respond to the target numbers.

Eligibility criteria:
inclusion criteria: 1. healthy subjects * capability of giving consent * ess (epworth sleepiness scale) score less than 9 * holding a driving license 2. patients * diagnostic osas * capability of giving consent * holding a driving licence exclusion criteria: 1. healthy subjects * suspected osas, any observed sleep disorders or snoring * acute cardial, pulmonal oder neurological disease 2. patients - acute cardial, pulmonal oder neurological disease

Keywords: alertness test sleepiness vigilance sleep apnea, obstructive
transabdominal cervical length predict preterm labor during routine antenatal screening

Conditions: Preterm Labor

Summary: sonographically, cervical length measurement is widely used in obstetrics. studies have revealed that early detection of short cervix can be a predictor of predicting preterm labor. transvaginal ultrasonography has been shown as a reference method for the recognition of the short cervix, as well as it may be useful in the transabdominal evaluation in the studies conducted. in addition to the advantages of transvaginal evaluation, it is time consuming and disadvantages of some women during anxiety and discomfort during this procedure. transabdominal ultrasonography, which provides a non-invasive evaluation, is more preferred by some patients than transvaginal. the aim of this study is to investigate the value of the cervical length measured by transabdominal route, which is a more acceptable method for pregnant women, in predicting preterm birth.

births that occur before 37th gestational week are an important cause of perinatal morbidity and mortality. preterm birth accounts for about 12% of all births. early screening and correct management of pregnant women at risk of preterm birth is essential in reducing perinatal mortality and morbidity associated with prematurity. but the precise prediction and prevention of preterm birth is still an important research topic. transabdominal ultrasonography, which provides a non-invasive evaluation, is more preferred by some patients than transvaginal.the aim of this study was to investigate the value of the cervical length measured by transabdominal route, which is a more acceptable method for pregnant women, in predicting preterm birth.

Eligibility criteria:
inclusion criteria: -pregnant women who gave birth in our clinic and have a 2nd trimester cervical length measurement exclusion criteria: * uterin anomaly * multiple pregnancy cases with a history of cervical surgery * termination of pregnancy due to fetal or maternal reasons

Keywords: ultrasonography transvaginal transabdominal second trimester preterm labor predict